irinotecan has been researched along with Sensitivity and Specificity in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (9.26) | 18.2507 |
| 2000's | 31 (57.41) | 29.6817 |
| 2010's | 17 (31.48) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Algül, H; Braren, R; Friess, H; Kaissis, G; Lohöfer, F; Muckenhuber, A; Rummeny, E; Schmid, R; Siveke, JT; Steiger, K; Weichert, W; Yen, HY; Ziegelmayer, S | 1 |
| Atias, D; Berger, R; Borgida, A; Cuggia, A; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Glick, Y; Golan, T; Grant, RC; Halperin, S; Holter, S; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Park, JP; Raitses-Gurevich, M; Renouf, DJ; Schaeffer, DF; Stossel, C; Wang, Y; Williamson, L; Wilson, JM; Wong, HL; Zhang, A; Zogopoulos, G | 1 |
| Cho, DH; Kim, CW; Kim, JC; Kim, MB; Kim, TW; Roh, SA; Yoon, YS | 1 |
| Bassi, C; Bonamini, D; Boninsegna, E; Manfredi, R; Marchegiani, G; Negrelli, R; Pozzi Mucelli, R; Salvia, R; Sureka, B; Todaro, V | 1 |
| Cao, Y; Chen, Y; Jiang, J; Kang, A; Qin, Y; Shi, Y; Tang, Y; Wang, H; Wang, J; Wei, W; Zhou, G | 1 |
| Albino, V; Fusco, R; Granata, V; Grimm, R; Izzo, F; Palaia, R; Petrillo, A; Piccirillo, M; Setola, SV | 1 |
| Cao, Y; Cheng, Q; Lu, H; Zhang, H | 1 |
| Hendel, HW; Jensen, BV; Nielsen, D; Skougaard, K | 1 |
| Ahn, G; Cho, JY; Jang, IJ; Kim, HK; Kim, HY; Park, DM; Park, JW; Rhee, SJ | 1 |
| Ghazaly, E; Joel, S; Kitromilidou, C; Perry, J; Powles, T | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Hummon, AB; Liu, X | 1 |
| Agostini, M; Calandra, E; Crotti, S; Giodini, L; Marangon, E; Nitti, D; Posocco, B; Toffoli, G; Traldi, P | 1 |
| Awasthi, A; Bansal, T; Jaggi, M; Khar, RK; Talegaonkar, S | 1 |
| D'Esposito, F; Murray, M; Ramzan, I; Tattam, BN | 1 |
| Edwards, CC; Hicks, LD; Hyatt, JL; Potter, PM; Stoddard, S; Tsurkan, L; Wadkins, RM | 1 |
| Cheng, YC; Dutschman, GE; Li, X; Ye, M; Zhang, W | 1 |
| Aladag, N; Aydinlik, S; Ozkan-Ariksoysal, D; Ozsoz, M; Topkaya, SN | 1 |
| Gizewski, ER; Lanzman, RS; Mathys, C; Mödder, U; Rapp, M; Ringelstein, A; Sabel, M; Saleh, A; Schroeteler, J; Turowski, B | 1 |
| Aucélio, RQ; da Cunha, AL; Marques, FF | 1 |
| Bedekar, DP; Donohoe, DL; Kurpad, SN; Pechman, KR; Schmainda, KM | 1 |
| Berglund, Å; Byström, P; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Bachelot, A; Baudin, E; Docao, C; Gicquel, C; Penfornis, A; Schlumberger, M; Vassal, G | 1 |
| Danesi, R; Di Paolo, A | 1 |
| Villalona-Calero, MA; Xu, Y | 1 |
| Crews, KR; Dodds, H; Fricke, K; Hanna, SK; Owens, TS | 1 |
| Ahmad, A; Ahmad, I; Dahhani, F; Guo, W; Khan, S; Wang, YF | 1 |
| de Bruijn, P; de Jong, FA; Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Enomoto, K; Maruyama, K; Matsui, A; Okuda, M; Tsujitsuka, K | 1 |
| Astre, C; Bressolle, F; Culine, S; Malosse, F; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Ahmad, A; Ahmad, I; Khan, S | 1 |
| Cloughesy, T; Filka, E; Fruehauf, JP; Mehta, R; Parker, RJ | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Cecchin, E; Toffoli, G | 1 |
| Dan, S; Fukui, Y; Nakamura, T; Nakatsu, N; Yamazaki, K; Yamori, T; Yoshida, Y | 1 |
| Arnold, CN; Blum, HE | 1 |
| Ahmad, A; Ahmad, I; Ayoub, J; Bardin, S; Duggan, JX; Guo, W; Johnson, JL; Khan, S | 1 |
| Chen, T; Chu, ZH; Liu, JP; Ou, QJ; Wang, J; Zhao, HY | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Denis, L; Duncan, BA; Erlichman, C; McGovren, P; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Sharma, A; Sloan, JA; Yin, D | 1 |
| Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M | 1 |
| Norum, J | 1 |
| Falk, S; Glynne-Jones, R; Maughan, TS; Meadows, HM; Sebag-Montefiore, D | 1 |
| Biesmans, B; De Hertogh, G; De Roock, W; De Schutter, J; Humblet, Y; Janssens, M; Peeters, M; Personeni, N; Piessevaux, H; Tejpar, S; Van Cutsem, E; Van Laethem, JL | 1 |
| Bissery, MC; Chabot, GG; Lavelle, F; Vrignaud, P | 1 |
| de Bruijn, P; de Jonge, MJ; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Dupuy, JL; Gaulier, JM; Lacassie, E; Lachâtre, F; Lachâtre, G; Marquet, P; Ragot, S; Rousseau, A | 1 |
| Handa, T; Kai, S; Kazami, A; Koizumi, K; Maruyama, M; Takemoto, N; Yamao, T | 1 |
| Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C | 1 |
| Iqbal, S; Lenz, HJ | 1 |
| Ando, M; Hanioka, N; Jinno, H; Nishimura, T; Ozawa, S; Sawada, J | 1 |
| Boyd, G; Cummings, J; Jodrell, DI; Smyth, JF | 1 |
| Kaniwa, N; Ozawa, S; Sai, K; Sawada, J | 1 |
6 review(s) available for irinotecan and Sensitivity and Specificity
| Article | Year |
|---|---|
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Topics: Animals; Apoptosis; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; NF-kappa B; Risk Assessment; Sensitivity and Specificity; Topoisomerase I Inhibitors | 2002 |
Pharmacology of intraperitoneal CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Parenteral; Irinotecan; Male; Maximum Tolerated Dose; Risk Assessment; Sensitivity and Specificity | 2003 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Sensitivity and Specificity; Toxicogenetics | 2004 |
[Colon cancer: molecular markers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Feces; Fluorouracil; Genes, ras; Genes, Tumor Suppressor; Genetic Markers; Humans; Irinotecan; Microsatellite Repeats; Mutation; Oncogenes; Polymerase Chain Reaction; Prognosis; Prospective Studies; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Determinants of prognosis and response to therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase | 2001 |
11 trial(s) available for irinotecan and Sensitivity and Specificity
| Article | Year |
|---|---|
Diffusion kurtosis imaging and conventional diffusion weighted imaging to assess electrochemotherapy response in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Diffusion Tensor Imaging; Electrochemotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Statistics, Nonparametric; Thermal Conductivity; Treatment Outcome | 2019 |
Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Denmark; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Humans; Irinotecan; Metabolic Clearance Rate; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Evaluation of predictive markers for patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C-Reactive Protein; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prealbumin; Predictive Value of Tests; Prognosis; Receptors, Albumin; Sensitivity and Specificity; Serum Amyloid A Protein; Sweden; Tissue Inhibitor of Metalloproteinase-1; Tissue Polypeptide Antigen | 2012 |
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Biopsy, Needle; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; France; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2002 |
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2002 |
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Stability; Glucuronates; Humans; Irinotecan; Neoplasm Metastasis; Reproducibility of Results; Saliva; Sensitivity and Specificity; Spectrometry, Fluorescence | 2003 |
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Powders; Sensitivity and Specificity | 2006 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Rectal Neoplasms; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Administration Schedule; Female; Fluorouracil; France; Health Care Costs; Hospital Costs; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Salvage Therapy; Sensitivity and Specificity; Survival Analysis | 2000 |
37 other study(ies) available for irinotecan and Sensitivity and Specificity
| Article | Year |
|---|---|
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Keratins, Hair-Specific; Keratins, Type II; Leucovorin; Machine Learning; Male; Middle Aged; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 2019 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Germ-Line Mutation; Homologous Recombination; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Recombinational DNA Repair; Sensitivity and Specificity; Survival Rate; Tumor Suppressor Protein p53; Whole Genome Sequencing | 2021 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2018 |
Carboxylesterase and UDP-glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra-performance liquid chromatography-mass spectrometry analysis.
Topics: Animals; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Glucuronosyltransferase; Humans; Irinotecan; Linear Models; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
[Determination of 7-ethyl-10-hydroxycamptothecin in microdialysates from rat brain with LC-MS/MS].
Topics: Animals; Brain Chemistry; Camptothecin; Chromatography, Liquid; Irinotecan; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
A rapid, simple and reliable HPLC-triple quadrupole tandem mass spectrometer method for a simultaneous quantification of irinotecan and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma.
Topics: Animals; Camptothecin; Chromatography, High Pressure Liquid; Female; Irinotecan; Linear Models; Male; Mice; Mice, Inbred ICR; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method.
Topics: Acetonitriles; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Stability; HCT116 Cells; HT29 Cells; Humans; Intracellular Space; Irinotecan; Least-Squares Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Tandem Mass Spectrometry | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Quantitative determination of irinotecan and the metabolite SN-38 by nanoflow liquid chromatography-tandem mass spectrometry in different regions of multicellular tumor spheroids.
Topics: Camptothecin; Chromatography, Liquid; Drug Stability; HCT116 Cells; Humans; Irinotecan; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spheroids, Cellular; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2015 |
Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies.
Topics: Animals; Bile; Camptothecin; Chromatography, High Pressure Liquid; Female; Irinotecan; Linear Models; Rats; Reference Standards; Sensitivity and Specificity; Time Factors; Ultraviolet Rays | 2008 |
A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, Liquid; Drug Stability; Humans; Irinotecan; Microsomes, Liver; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2008 |
Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
Topics: Camptothecin; Carboxylic Ester Hydrolases; Drug Design; Enzyme Inhibitors; Humans; Intestines; Irinotecan; Molecular Structure; Quantitative Structure-Activity Relationship; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism; Substrate Specificity | 2009 |
Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, Liquid; Glucuronates; Glucuronidase; Humans; Irinotecan; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Different DNA immobilization strategies for the interaction of anticancer drug irinotecan with DNA based on electrochemical DNA biosensors.
Topics: Adsorption; Animals; Antineoplastic Agents; Biosensing Techniques; Camptothecin; DNA; Electrochemistry; Electrodes; Fishes; Graphite; High-Throughput Screening Assays; Irinotecan; Male; Oligonucleotides; Oxidation-Reduction; Sensitivity and Specificity; Spermatozoa; Surface Properties | 2010 |
[Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Gadolinium; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Male; Neoplasm Recurrence, Local; Sensitivity and Specificity; Vascular Endothelial Growth Factor A | 2010 |
Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fluorescence; Irinotecan; Lasers; Pharmaceutical Preparations; Photochemistry; Sensitivity and Specificity; Spectrometry, Fluorescence; Topotecan | 2010 |
Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Volume; Blood Volume Determination; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cerebrovascular Circulation; Irinotecan; Magnetic Resonance Imaging; Male; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2012 |
High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Humans; Irinotecan; Lactones; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2003 |
Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Dogs; Enzyme Inhibitors; Irinotecan; Liposomes; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2003 |
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Erythrocytes; Humans; Irinotecan; Reproducibility of Results; Sensitivity and Specificity; Topoisomerase I Inhibitors | 2003 |
A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).
Topics: Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Liposomes; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cluster Analysis; Computational Biology; Databases as Topic; DNA, Complementary; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mitomycin; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phylogeny; Sensitivity and Specificity; Tissue Distribution; Transfection; Vinblastine; Vinorelbine | 2005 |
Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mass Spectrometry; Mice; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2005 |
[Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Sensitivity and Specificity; Survival Rate | 2005 |
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Irinotecan; Middle Aged; Models, Theoretical; Neoplasm Metastasis; Sensitivity and Specificity | 2006 |
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed | 2008 |
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Sensitivity and Specificity; Taxoids; Vincristine | 1996 |
Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Sensitivity and Specificity | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry.
Topics: Acetonitriles; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Precipitation; Chromatography, High Pressure Liquid; Humans; Irinotecan; Male; Mass Spectrometry; Neoplasms; Reproducibility of Results; Sensitivity and Specificity | 1999 |
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Stomach Neoplasms; Survival Rate | 1999 |
High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes.
Topics: Camptothecin; Chromatography, High Pressure Liquid; Glucuronides; Humans; Irinotecan; Microsomes, Liver; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2001 |
High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.
Topics: Camptothecin; Cell Extracts; Chromatography, High Pressure Liquid; Colonic Neoplasms; Culture Media; Drug Stability; HT29 Cells; Humans; Irinotecan; Lactones; Reproducibility of Results; Sensitivity and Specificity; Sonication; Time Factors | 2001 |
An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Mass Spectrometry; Microsomes, Liver; Reference Standards; Sensitivity and Specificity; Spectrometry, Fluorescence | 2002 |